Clinical trial
Temozolomide in Treating Patients With Anaplastic Oligodendroglioma
NCT00003465 · Duke University, Other · Completed
Key facts
| NCT number | NCT00003465 |
|---|---|
| Title | Temozolomide in Treating Patients With Anaplastic Oligodendroglioma |
| Official title | Phase II Treatment of Adults With Newly Diagnosed, Progressive or Recurrent Primary Malignant Anaplastic Oligodendroglioma With Temodal |
| Lead sponsor | Duke University, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Brain and Central Nervous System Tumors |
| Intervention type | Drug |
| Interventions | temozolomide |
| Enrollment | 60 |
| Start date | Mar 1, 1998 |
| Completion | Feb 1, 2001 |
| First posted | Mar 12, 2004 |
| Last update posted | Jun 20, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: